Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 215

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Emergence of New ALK Mutations at Relapse of Neuroblastoma

Schleiermacher, Gudrun, Javanmardi, Niloufar, Bernard, Virginie, Leroy, Quentin, Cappo, Julie, Rio Frio, Thomas, Pierron, Gaelle, Lapouble, Eve, Combaret, Valérie, Speleman, Frank, de Wilde, Bram, Djos, Anna, Øra, Ingrid, Hedborg, Fredrik, Träger, Catarina, Holmqvist, Britt-Marie, Abrahamsson, Jonas, Peuchmaur, Michel, Michon, Jean, Janoueix-Lerosey, Isabelle, Kogner, Per, Delattre, Olivier, Martinsson, Tommy·2014·Journal of Clinical Oncology

Abstract

Purpose: In neuroblastoma, the ALK receptor tyrosine kinase is activated by point mutations. We investigated the potential role of ALK mutations in neuroblastoma clonal evolution. Methods: We analyzed ALK mutations in 54 paired diagnosis–relapse neuroblastoma samples using Sanger sequencing. When an ALK mutation was observed in one paired sample, a minor mutated component in the other sample was searched for by more than 100,000× deep sequencing of the relevant hotspot, with a sensitivity of 0.17%. Results: All nine ALK-mutated cases at diagnosis demonstrated the same mutation at relapse, in one case in only one of several relapse nodules. In five additional cases, the mutation seemed to be relapse specific, four of which were investigated by deep sequencing. In two cases, no mutation evidence was observed at diagnosis. In one case, the mutation was present at a subclonal level (0.798%) at diagnosis, whereas in another case, two different mutations resulting in identical amino acid changes were detected, one only at diagnosis and the other only at relapse. Further evidence of clonal evolution of ALK-mutated cells was provided by establishment of a fully ALK-mutated cell line from a primary sample with an ALK-mutated cell population at subclonal level (6.6%). Conclusion: In neuroblastoma, subclonal ALK mutations can be present at diagnosis with subsequent clonal expansion at relapse. Given the potential of ALK-targeted therapy, the significant spatiotemporal variation of ALK mutations is of utmost importance, highlighting the potential of deep sequencing for detection of subclonal mutations with a sensitivity 100-fold that of Sanger sequencing and the importance of serial samplings for therapeutic decisions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2013.54.0674

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 215

Metadata

Authors
Schleiermacher, G., Javanmardi, N., Bernard, V., Leroy, Q., Cappo, J., Rio Frio, T., Pierron, G., Lapouble, E., Combaret, V., Speleman, F., de Wilde, B., Djos, A., Øra, I., Hedborg, F., Träger, C., Holmqvist, B.-M., Abrahamsson, J., Peuchmaur, M., Michon, J., Janoueix-Lerosey, I., Kogner, P., Delattre, O., & Martinsson, T.
Venue
Journal of Clinical Oncology
Published
2014-09-01
Volume
32
Issue
25
Pages
2727-2734
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2151322893
Cited by
215
References
4
FWCI
12.22
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Emergence of New ALK Mutations at Relapse of Neuroblastoma. https://app.cochat.ai/papers/10.1200/jco.2013.54.0674
The paper
Schleiermacher, G., Javanmardi, N., Bernard, V., Leroy, Q., Cappo, J., Rio Frio, T., Pierron, G., Lapouble, E., Combaret, V., Speleman, F., de Wilde, B., Djos, A., Øra, I., Hedborg, F., Träger, C., Holmqvist, B.-M., Abrahamsson, J., Peuchmaur, M., Michon, J., . . . Martinsson, T. (2014). Emergence of New ALK Mutations at Relapse of Neuroblastoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2013.54.0674

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.